Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00659425 · ClinicalTrials.gov registry record · Phase 1
CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
NCT00659425 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 57 participants.
The verdict
NCT00659425, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
Study Summary
A dose-escalation study to estimate maximum cummulative dose (MTCD) of CAT-8015 that can be safely administered to a participant.
Interventions
- DRUG CAT-8015 (Moxetumomab Pasudotox)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2008-09 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00659425
The ClinicalTrials.gov registry entry for NCT00659425 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CAT-8015 (Moxetumomab Pasudotox) is the first listed.
NCT00659425 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00659425 about?
NCT00659425 is a clinical study titled "CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma". A dose-escalation study to estimate maximum cummulative dose (MTCD) of CAT-8015 that can be safely administered to a participant.
What is the current status of trial NCT00659425?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2008-09. Estimated completion is 2014-12.
What interventions are being tested in trial NCT00659425?
The interventions under investigation include: CAT-8015 (Moxetumomab Pasudotox) (DRUG).
Who is sponsoring clinical trial NCT00659425?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.